125 related articles for article (PubMed ID: 3028121)
1. Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors.
Pastolero GC; Wakabayashi T; Oka T; Mori S
Am J Clin Pathol; 1987 Feb; 87(2):168-73. PubMed ID: 3028121
[TBL] [Abstract][Full Text] [Related]
2. [An immunohistochemical study on primary carcinoma of the liver].
Seo JK
J UOEH; 1989 Dec; 11(4):429-39. PubMed ID: 2481871
[TBL] [Abstract][Full Text] [Related]
3. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections.
Balaton AJ; Nehama-Sibony M; Gotheil C; Callard P; Baviera EE
J Pathol; 1988 Dec; 156(4):305-10. PubMed ID: 2465399
[TBL] [Abstract][Full Text] [Related]
4. Epithelial membrane antigen expression in cholangiocarcinoma. An useful immunohistochemical tool for differential diagnosis with hepatocarcinoma.
Bonetti F; Chilosi M; Pisa R; Novelli P; Zamboni G; Menestrina F
Virchows Arch A Pathol Anat Histopathol; 1983; 401(3):307-13. PubMed ID: 6314640
[TBL] [Abstract][Full Text] [Related]
5. Blood-group-related antigen Lewis(x) and Lewis(y) in the differential diagnosis of cholangiocarcinoma and hepatocellular carcinoma.
Jovanovic R; Jagirdar J; Thung SN; Paronetto F
Arch Pathol Lab Med; 1989 Feb; 113(2):139-42. PubMed ID: 2537068
[TBL] [Abstract][Full Text] [Related]
6. Letter: Alpha fetoprotein and cholangiocellular carcinoma.
Villeneuve JP; Richer G; Côté J; Joly JG; Marleau D; Viallet A
N Engl J Med; 1974 May; 290(22):1260. PubMed ID: 4133098
[No Abstract] [Full Text] [Related]
7. Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
Haglund C; Lindgren J; Roberts PJ; Nordling S
Br J Cancer; 1991 Mar; 63(3):386-9. PubMed ID: 1848439
[TBL] [Abstract][Full Text] [Related]
8. [Tissue polypeptide antigen (TPA) in liver tissue from patients with hepatocellular carcinoma].
Onji M; Danjo K; Miyaoka H; Taniguchi Y; Ohta Y
Nihon Shokakibyo Gakkai Zasshi; 1987 Nov; 84(11):2537-41. PubMed ID: 2831415
[No Abstract] [Full Text] [Related]
9. Immunohistochemistry in the differential diagnosis of liver carcinomas.
Hurlimann J; Gardiol D
Am J Surg Pathol; 1991 Mar; 15(3):280-8. PubMed ID: 1847609
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H
Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases.
Okuda K; Kubo Y; Okazaki N; Arishima T; Hashimoto M
Cancer; 1977 Jan; 39(1):232-46. PubMed ID: 64293
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of alpha1-fetoprotein, bile antigen VIII and Australia (HB) antigen in primary cancer of the liver.
Luca N; Luca R
Med Interne; 1977; 15(4):369-73. PubMed ID: 74084
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.
Goodman ZD; Ishak KG; Langloss JM; Sesterhenn IA; Rabin L
Cancer; 1985 Jan; 55(1):124-35. PubMed ID: 2578078
[TBL] [Abstract][Full Text] [Related]
14. Expression of ABH and Lewis blood group antigens in combined hepatocellular-cholangiocarcinoma. Possible evidence for the hepatocellular origin of combined hepatocellular-cholangiocarcinoma.
Okada Y; Jinno K; Moriwaki S; Morichika S; Torigoe S; Arima T; Nagashima H; Koprowski H
Cancer; 1987 Aug; 60(3):345-52. PubMed ID: 3036328
[TBL] [Abstract][Full Text] [Related]
15. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
16. The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma.
Kew MC; Berger EL
Cancer; 1986 Jul; 58(1):127-30. PubMed ID: 2423221
[TBL] [Abstract][Full Text] [Related]
17. Fibronectin in differential diagnosis of primary hepatomas and carcinoma metastases in the liver.
Szendröi M; Lapis K
Acta Morphol Hung; 1985; 33(1-2):101-9. PubMed ID: 3012968
[TBL] [Abstract][Full Text] [Related]
18. [The clinical evaluation of serum tissue polypeptide antigen (TPA) in hepatocellular carcinoma].
Tanaka N; Yamada S; Tsuchiya M; Etoh K
Fukuoka Igaku Zasshi; 1984 Sep; 75(9):568-73. PubMed ID: 6097524
[No Abstract] [Full Text] [Related]
19. A distinctive antigen present in liver carcinomas induced by 3'-methyl-p-dimethylaminoazobenzene.
Carruthers C; Baumler A; Neilson A
Oncology; 1977; 34(2):47-51. PubMed ID: 70767
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma.
Johnson DE; Herndier BG; Medeiros LJ; Warnke RA; Rouse RV
Am J Surg Pathol; 1988 Mar; 12(3):187-97. PubMed ID: 2449824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
